Background: Leishmania infantum is the only prevalent Leishmania species in Europe and manifesting predominantly as cutaneous or visceral leishmaniasis, whereas new world species like Leishmania (L.) braziliensis are well known pathogens in mucocutaneous leishmaniasis. Mucosal leishmaniasis caused by L. infantum is a rare clinical condition with only few cases described in literature. In contrast to our case, mostly immunocompromised patients with no history of leishmaniasis are affected.
Case Presentation: We describe the case of a 77-year-old German male who developed an ulcerous lesion of the tongue. As oral cancer was suspected, the patient underwent surgery. After suspected diagnosis of Leishmania spp. in histopathology, the patient was referred to our department for further diagnostics and treatment. Relapse from a cutaneous leishmaniasis acquired in Spain is likely, as L. infantum could be identified as the causative agent. The patient recovered after treatment.
Conclusions: Mucosal leishmaniasis caused by L. infantum is rare and usually mistaken for malignancy. As demonstrated, it can be preceded by cutaneous leishmaniasis of the immunocompetent. Due to possible dissemination systemic treatment should be applied.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11837717 | PMC |
| http://dx.doi.org/10.1186/s12879-025-10592-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Borderline Disseminated (Intermediate) Cutaneous Leishmaniasis: A Case-Based Approach to Diagnosis and Clinical Management in Pediatric Population.
Pediatr Infect Dis J
March 2025
Icahn School of Medicine at Mount Sinai, New York, New York.
Background: Cutaneous leishmaniasis (CL) is a neglected tropical disease with diverse clinical manifestations, ranging from localized CL to severe forms such as diffuse CL and mucocutaneous leishmaniasis. Borderline disseminated CL (BDCL), an intermediate form, is characterized by multiple disseminated lesions and poses unique diagnostic and therapeutic challenges, especially in pediatric patients. This study explores pediatric BDCL to better understand its clinical presentation, diagnostic approaches and treatment outcomes.
View Article and Find Full Text PDFA case of laryngeal leishmaniasis presenting as hoarseness in an Ethiopian patient: a case report.
J Med Case Rep
March 2025
Internal Medicine Department, Addis Ababa University, Addis Ababa, Ethiopia.
Background: Leishmaniasis is a zoonotic disease caused by unicellular protozoa of the Leishmania genus. The infection can spread through zoonotic or anthroponotic transmission, depending on the species, with the phlebotomine sandfly serving as the primary vector. Leishmaniasis is endemic in tropical regions of Asia and Africa.
View Article and Find Full Text PDFAdequacy of nutritional status and dietary intake of adult and elderly patients with American Tegumentary Leishmaniasis.
Einstein (Sao Paulo)
February 2025
Laboratório de Pesquisa Clínica e Vigilância em Leishmanioses, Instituto Nacional de Infectologia Evandro Chagas, Fundação Oswaldo Cruz (Fiocruz), Rio de Janeiro, RJ, Brazil.
Background: This cross-sectional study describes the adequacy of nutritional status and food intake in patients with American Tegumentary Leishmaniasis and its relationship with the form of the disease: cutaneous or mucosal. Patients with mucosal have greater nutritional impairment associated with older age and symptoms such as odynophagia, dysphagia, and oropharyngeal lesions, which lead to reduced dietary intake and inadequate intake of micronutrients.
Objective: Patients with American Tegumentary Leishmaniasis often experience malnutrition, weight loss, and dehydration; however, their eating profile and the degree of interference of disease manifestations on food intake is not well understood.
Cytokine Networks and the Clinical Outcome of American Teg-Umentary Leishmaniasis: Unveiling Targets for Alternative Therapeutic Interventions.
Pathogens
February 2025
Department of Morphology, Institute of Biological Sciences, Federal University of Minas Gerais, Av. Pres. Antônio Carlos, 6627-Pampulha, Belo Horizonte 31270-901, MG, Brazil.
American Tegumentary Leishmaniasis (ATL), caused by parasites of the genus , presents a significant global health challenge, especially in Brazil, where cutaneous and mucosal forms are highly prevalent. Cutaneous Leishmaniasis (CL) typically results in single lesions, while mucosal Leishmaniasis (ML) leads to destructive mucosal lesions with a worse prognosis. The immune response, regulated by cytokines, plays a crucial role in disease progression and resolution.
View Article and Find Full Text PDFInhaled Pentamidine for Bolivian Mucosal Leishmaniasis.
Am J Trop Med Hyg
February 2025
AB Foundation, North Bethesda, Maryland.
Aerosolized pentamidine is Food and Drug Administration approved to treat Pneumocystis pneumonia via a route that does not lead to systemic absorption or toxicity. Because Leishmania is also susceptible to pentamidine and mucosal leishmaniasis is also an infection of the respiratory tract, we performed a pilot study of aerosolized pentamidine (300 mg for 10 days over approximately 4 weeks) for mucosal leishmaniasis caused by Bolivian Leishmania braziliensis with a 2-year follow-up. Of 15 patients, 6 of 7 patients with initially mild disease were cured, 3 of 4 patients with initially moderate disease relapsed at the 18- to 24-month follow-up visits, and 3 of 4 patients with initially severe disease failed early after treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!